Table 1.
Patients’ characteristics at baseline.
| Characteristics | All Patients | FOLFOXIRI Cohort | GemNab Cohort | |||
|---|---|---|---|---|---|---|
| n = 138 | % | n = 81 | % | n = 57 | % | |
| Age years, median (range) | 64 (41–76) | - | 62 (41–75) | - | 68 (47–76) | |
| Age (years) | ||||||
| <65 | 80 | 58 | 60 | 74 | 20 | 35 |
| ≥65 | 58 | 42 | 21 | 26 | 37 | 65 |
| Gender | ||||||
| Male | 71 | 51.4 | 40 | 49.4 | 31 | 54.4 |
| Female | 67 | 48.6 | 41 | 50.6 | 26 | 45.6 |
| ECOG Performance Status | ||||||
| 0 | 84 | 68.4 | 62 | 76.5 | 22 | 38.6 |
| 1 | 54 | 39.2 | 19 | 23.5 | 35 | 61.4 |
| Histology: Adenocarcinoma | ||||||
| Ductal | 123 | 89.1 | 74 | 91.4 | 49 | 86 |
| On IPMN | 12 | 8.7 | 6 | 7.4 | 6 | 10.6 |
| Acinar | 2 | 1.4 | 1 | 1.2 | 1 | 1.7 |
| Squamous | 1 | 0.7 | - | - | 1 | 1.7 |
| Site of primitive tumor | ||||||
| Head/uncinate process | 65 | 47.1 | 39 | 48.1 | 26 | 45.6 |
| Body/tail | 73 | 52.9 | 42 | 51.9 | 31 | 54.4 |
| Number of metastatic sites | ||||||
| Median (range) | 2 (1–5) | - | 2 (1–5) | 2 (1–4) | ||
| Synchronous disease | ||||||
| Yes | 101 | 73.2 | 58 | 71.6 | 43 | 75.4 |
| No | 37 | 26.8 | 23 | 28.4 | 14 | 24.6 |
| Metastatic sites | ||||||
| Liver | 108 | 78.3 | 65 | 80.2 | 43 | 75.4 |
| Peritoneum | 41 | 29.7 | 27 | 33.3 | 14 | 24.6 |
| Lung | 32 | 23.2 | 14 | 17.3 | 18 | 31.6 |
| Bones | 4 | 2.9 | 2 | 2.5 | 2 | 3.5 |
| Local recurrence | 7 | 5.1 | 3 | 3.7 | 4 | 7 |
| Lymph nodes | 20 | 14.4 | 4 | 4.8 | 16 | 28 |
| Previous treatments | ||||||
| Curative-intent surgery | 37 | 26.9 | 24 | 29.6 | 13 | 22.8 |
| Adjuvant chemotherapy | 25 | 18.1 | 18 | 22.2 | 7 | 12.3 |
| Ca 19.9 [KU/L] | ||||||
| Normal value | 27 | 19.5 | 15 | 18.5 | 13 | 22.8 |
| <59 ULN | 60 | 43.4 | 39 | 48.1 | 22 | 38.6 |
| ≥59 ULN | 42 | 30.4 | 20 | 24.7 | 20 | 35.1 |
| Not evaluable | 9 | 6.5 | 7 | 8.6 | 2 | 3.5 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; Gemcitabine Nab-Paclitaxel (GemNab); IPMN, Intraductal papillary mucinous neoplasm; ULN, Upper Limit of Normal.